ReViral – Innovative therapies for viral diseases
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
Location: United Kingdom, England, Stevenage
Employees: 11-50
Total raised: $99M
Founded date: 2011
Investors 5
Date | Name | Website |
- | Brace Phar... | bracepharm... |
- | Andera Par... | anderapart... |
- | OrbiMed | orbimed.co... |
- | Perceptive... | perceptive... |
- | New Leaf V... | nlvpartner... |
Funding Rounds 2
Date | Series | Amount | Investors |
01.09.2020 | Series C | $44M | - |
01.08.2018 | Series B | $55M | New Leaf V... |
Mentions in press and media 16
Date | Title | Description | Source |
07.04.2022 | A-Rod-backed sports betting app Mojo wants to let you bet on... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
01.09.2020 | SBC company ReViral raises $44 million in Series C financing | London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company... | cambridgen... |
01.09.2020 | SBC company ReViral raises $44 million in Series C financing | SBC company ReViral raises $44 million in Series C financing 01-09-2020 London & Research Tria... | cambridgen... |
28.08.2020 | Reviral raises $44 million in Series C financing | ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and c... | anderapart... |
27.08.2020 | UK biopharma startup ReViral lands $44M Series C | CR-CP Life Science Fund, the joint VC vehicle of Charoen Pokphand Group and China Resources Capital ... | pitchbook.... |
25.08.2020 | ReViral Raises $44 Million in Series C Financing | - | orbimed.co... |
10.12.2018 | Cambridge companies feature in SyndicateRoom's Top 100 | Cambridge companies feature in SyndicateRoom's Top 100 10-12-2018 What are the hottest companies o... | cambridgen... |
02.08.2018 | Term Sheet — Thursday, August 2 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content Securing the enterprise witho... | fortune.co... |
01.08.2018 | ReViral closes $55 million Series B funding round for RSV dr... | The company plans to use the funding to move its lead drug candidate, RV521, into Phase IIa studies ... | medcitynew... |
01.08.2018 | ReViral gets a $55M booster shot of cash as it expands i... | Six months after ReViral outlined the efficacy of their respiratory syncytial virus, or... | endpts.com... |
Show more